Steroid-independent activation of androgen receptor in androgen-independent prostate cancer. A possible role for the MAP kinase signal transduction pathway?

Molecular and Cellular Endocrinology

Volumn 134, Issue 1, 1997, Pages 9-14

  Zhu, X ^a   Liu, J P ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

Androgen independence; Androgen receptor; MAP kinase; Phosphorylation; Prostate cancer

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE;

APOPTOSIS; GENE; HORMONE RESISTANCE; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; STRESS;

ANIMALS; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION;

EID: 0030699973     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0303-7207(97)00168-8     Document Type: Review

References (56)

1. Darbre P.D., King R.J. Interaction of different steroid hormones during progression of tumour cells to steroid autonomy. Int. J. Cancer. 40:1987;802-806.
2. Luthy I., Labrie F. Development of androgen resistance in mouse mammary tumor cells can be prevented by the antiandrogen flutamide. Prostate. 10:1987;89-94.
3. Klocker H., Neuschmid-Kaspar F., Culig Z., Cato A.C., Hobisch A., Eberle J., Cronauer M.V., Hittmair A., Radmayr C., Uberreiter S.et al. Androgen receptor alterations in patients with disturbances in male sexual development and in prostatic carcinoma. Urol. Int. 54:1995;2-5.
4. Hobisch A., Culig Z., Radmayr C., Bartsch G., Klocker H., Hittmair A. Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res. 55:1995;3068-3072.
5. Kokontis J., Takakura K., Hay N., Liao S. Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. Cancer Res. 54:1994;1566-1573.
6. Evans B.A., Harper M.E., Daniells C.E., Watts C.E., Matenhelia S., Green J., Griffiths K. Low incidence of androgen receptor gene mutations in human prostatic tumors using single strand conformation polymorphism analysis. Prostate. 28:1996;162-171.
7. Brinkmann A.O., Jenster G., Ris-Stalpers C., van der Korput J.A., Bruggenwirth H.T., Boehmer A.L., Trapman J. Androgen receptor mutations. J. Steroid Biochem. Mol. Biol. 53:1995;443-448.
8. Furuya Y., Shirasawa H., Sato N., Watabe Y., Simizu B., Shimazaki J. Loss of androgen dependency with preservation of functional androgen receptors in androgen-dependent mouse tumor (Shionogi Carcinoma 115). J. Steroid Biochem. Mol. Biol. 42:1992;569-574.
9. Taplin M.E., Bubley G.J., Shuster T.D., Frantz M.E., Spooner A.E., Ogata G.K., Keer H.N., Balk S.P. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. New Engl. J. Med. 332:1995;1393-1398.
10. el-Shirbiny A.M. Prostatic specific antigen. Adv. Clin. Chem. 31:1994;99-133.
11. Gleave M.E., Hsieh J.T., Wu H.C., von Eschenbach A.C., Chung L.W. Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors. Cancer Res. 52:1992;1598-1605.
12. Kyprianou N., English H.F., Isaacs J.T. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res. 50:1990;3748-3753.
13. Isaacs J.T., Furuya Y., Berges R. The role of androgen in the regulation of programmed cell death/apoptosis in normal and malignant prostatic tissue. Semin. Cancer Biol. 5:1994;391-400.
14. Denmeade S.R., Lin X.S., Isaacs J.T. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate. 28:1996;251-265.
15. Kuiper G.G., Brinkmann A.O. Steroid hormone receptor phosphorylation: is there a physiological role? Mol. Cell. Endocrinol. 100:1994;103-107.
16. Orti E., Hu L.M., Munck A. Kinetics of glucocorticoid receptor phosphorylation in intact cells. Evidence for hormone-induced hyperphosphorylation after activation and recycling of hyperphosphorylated receptors. J. Biol. Chem. 268:1993;7779-7784.
17. Arnold S.F., Vorojeikina D.P., Notides A.C. Phosphorylation of tyrosine 537 on the human estrogen receptor is required for binding to an estrogen response element. J. Biol. Chem. 270:1995;30205-30212.
18. Denner L.A., Weigel N.L., Maxwell B.L., Schrader W.T., O'Malley B.W. Regulation of progesterone receptor-mediated transcription by phosphorylation. Science. 250:1990;1740-1743.
19. Bai W., Tullos S., Weigel N.L. Phosphorylation of Ser530 facilitates hormone-dependent transcriptional activation of the chicken progesterone receptor. Mol. Endocrinol. 8:1994;1465-1473.
20. Hu L.M., Bodwell J., Hu J.M., Orti E., Munck A. Glucocorticoid receptors in ATP-depleted cells: dephosphorylation, loss of hormone binding, hsp90 dissociation, and ATP-dependent cycling. J. Biol. Chem. 269:1994;6571-6577.
21. Kuiper G.G., Brinkmann A.O. Phosphotryptic peptide analysis of the human androgen receptor: detection of a hormone-induced phosphopeptide. Biochemistry. 34:1995;1851-1857.
22. van Laar J.H., Berrevoets C.A., Trapman J., Zegers N.D., Brinkmann A.O. Hormone-dependent androgen receptor phosphorylation is accompanied by receptor transformation in human lymph node carcinoma of the prostate cells. J. Biol. Chem. 266:1991;3734-3738.
23. Nazareth L.V., Weigel N.L. Activation of the human androgen receptor through a protein kinase A signaling pathway. J. Biol. Chem. 271:1996;19900-19907.
24. Culig Z., Hobisch A., Cronauer M.V., Hittmair A., Radmayr C., Bartsch G., Klocker H. Activation of the androgen receptor by polypeptide growth factors and cellular regulators. World J. Urol. 13:1995;285-289.
25. Culig Z., Hobisch A., Cronauer M.V., Radmayr C., Trapman J., Hittmair A., Bartsch G., Klocker H. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res. 54:1994;5474-5478.
26. Iwamura M., Sluss P.M., Casamento J.B., Cockett A.T. Insulin-like growth factor I: action and receptor characterization in human prostate cancer cell lines. Prostate. 22:1993;243-252.
27. Bunone G., Briand P.A., Miksicek R.J., Picard D. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J. 15:1996;2174-2183.
28. Pearson R.B., Kemp B.E. Protein kinase phosphorylation site sequences and consensus specificity motifs: tabulations. Methods Enzymol. 200:1991;62-81.
29. Zhou Z.X., Kemppainen J.A., Wilson E.M. Identification of three proline-directed phosphorylation sites in the human androgen receptor. Mol. Endocrinol. 9:1995;605-615.
30. Auricchio F. Phosphorylation of steroid receptors. J. Steroid. Biochem. 32:1989;613-622.
31. Jiang Y., Chen C., Li Z., Guo W., Gegner J.A., Lin S., Han J. Characterization of the structure and function of a new mitogen-activated protein kinase (p38β). J. Biol. Chem. 271:1996;17920-17926.
32. Coso O.A., Chiariello M., Yu J.C., Teramoto H., Crespo P., Xu N., Miki T., Gutkind J.S. The small GTP-binding proteins Rac1 and Cdc42 regulate the activity of the JNK/SAPK signaling pathway. Cell. 81:1995;1137-1146.
33. Crews C.M., Erikson R.L. Extracellular signals and reversible protein phosphorylation: what to Mek of it all. Cell. 74:1993;215-217.
34. Clarke P.R. Signal transduction. Switching off MAP kinases. Curr. Biol. 4:1994;647-650.
35. Kato S., Endoh H., Masuhiro Y., Kitamoto T., Uchiyama S., Sasaki H., Masushige S., Gotoh Y., Nishida E., Kawashima H.et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science. 270:1995;1491-1494.
36. Mukku V.R., Stancel G.M. Regulation of epidermal growth factor receptor by estrogen. J. Biol. Chem. 260:1985;9820-9824.
37. Migliaccio A., Di Domenico M., Castoria G., de Falco A., Bontempo P., Nola E., Auricchio F. Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. EMBO J. 15:1996;1292-1300.
38. Kyprianou N., Isaacs J.T. Identification of a cellular receptor for transforming growth factor-beta in rat ventral prostate and its negative regulation by androgens. Endocrinology. 123:1988;2124-2131.
39. Knabbe C., Klein H., Zugmaier G., Voigt K.D. Hormonal regulation of transforming growth factor beta-2 expression in human prostate cancer. J. Steroid Biochem. Mol. Biol. 47:1993;137-142.
40. Liu J.P. Protein kinase C and its substrates. Mol. Cell. Endocrinol. 116:1996;1-29.
41. Whitmarsh A.J., Shore P., Sharrocks A.D., Davis R.J. Integration of MAP kinase signal transduction pathways at the serum response element. Science. 269:1995;403-407.
42. Marais R., Light Y., Paterson H.F., Marshall C.J. Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation. EMBO J. 14:1995;3136-3145.
43. Teramoto H., Crespo P., Coso O.A., Igishi T., Xu N., Gutkind J.S. The small GTP-binding protein rho activates c-Jun N-terminal kinases/stress-activated protein kinases in human kidney 293T cells. Evidence for a Pak-independent signaling pathway. J. Biol. Chem. 271:1996;25731-25734.
44. Rana A., Gallo K., Godowski P., Hirai S., Ohno S., Zon L., Kyriakis J.M., Avruch J. The mixed lineage kinase SPRK phosphorylates and activates the stress-activated protein kinase activator, SEK-1. J. Biol. Chem. 271:1996;19025-19028.
45. Ichijo H., Nishida E., Irie K., ten Dijke P., Saitoh M., Moriguchi T., Takagi M., Matsumoto K., Miyazono K., Gotoh Y. Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science. 275:1997;90-94.
46. Pandey P., Raingeaud J., Kaneki M., Weichselbaum R., Davis R.J., Kufe D., Kharbanda S. Activation of p38 mitogen-activated protein kinase by c-Abl-dependent and -independent mechanisms. J. Biol. Chem. 271:1996;23775-23779.
47. Davis R.J. MAPKs: new JNK expands the group. Trends Biochem. Sci. 19:1994;470-473.
48. Kyprianou N., Isaacs J.T. Expression of transforming growth factor-beta in the rat ventral prostate during castration-induced programmed cell death. Mol. Endocrinol. 3:1989;1515-1522.
49. 31P magnetic resonance spectroscopy, creatine kinase activity, and apoptotic index. Cancer Res. 55:1995;4146-4150.
50. Perry R.R., Kang Y., Greaves B. Effects of tamoxifen on growth and apoptosis of estrogen-dependent and -independent human breast cancer cells. Ann. Surg. Oncol. 2:1995;238-245.
51. Verheij M., Bose R., Lin X.H., Yao B., Jarvis W.D., Grant S., Birrer M.J., Szabo E., Zon L.I., Kyriakis J.M., Haimovitz-Friedman A., Fuks Z., Kolesnick R.N. Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis. Nature. 380:1996;75-79.
52. Xia Z., Dickens M., Raingeaud J., Davis R.J., Greenberg M.E. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science. 270:1995;1326-1331.
53. Gupta S., Barrett T., Whitmarsh A.J., Cavanagh J., Sluss H.K., Derijard B., Davis R.J. Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J. 15:1996;2760-2770.
54. Jonat C., Rahmsdorf H.J., Park K.K., Cato A.C., Gebel S., Ponta H., Herrlich P. Antitumor promotion and antiinflammation: down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone. Cell. 62:1990;1189-1204.
55. Schule R., Rangarajan P., Kliewer S., Ransone L.J., Bolado J., Yang N., Verma I.M., Evans R.M. Functional antagonism between oncoprotein c-Jun and the glucocorticoid receptor. Cell. 62:1990;1217-1226.
56. Bubulya A., Wise S.C., Shen X.Q., Burmeister L.A., Shemshedini L. c-Jun can mediate androgen receptor-induced transactivation. J. Biol. Chem. 271:1996;24583-24589.